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Abstract
Background: The quest to understand the neurobiology of schizophrenia and bipolar disorder is ongoing with multiple
lines of evidence indicating abnormalities of glia, mitochondria, and glutamate in both disorders. Despite high heritability
estimates of 81% for schizophrenia and 75% for bipolar disorder, compelling links between findings from neurobiological
studies, and findings from large-scale genetic analyses, are only beginning to emerge.
Method: Ten publically available gene sets (pathways) related to glia, mitochondria, and glutamate were tested for
association to schizophrenia and bipolar disorder using MAGENTA as the primary analysis method. To determine the
robustness of associations, secondary analyses were performed with: ALIGATOR, INRICH, and Set Screen. Data from the
Psychiatric Genomics Consortium (PGC) were used for all analyses. There were 1,068,286 SNP-level p-values for
schizophrenia (9,394 cases/12,462 controls), and 2,088,878 SNP-level p-values for bipolar disorder (7,481 cases/9,250
controls).
Results: The Glia-Oligodendrocyte pathway was associated with schizophrenia, after correction for multiple tests, according
to primary analysis (MAGENTA p= 0.0005, 75% requirement for individual gene significance) and also achieved nominal
levels of significance with INRICH (p = 0.0057) and ALIGATOR (p = 0.022). For bipolar disorder, Set Screen yielded nominally
and method-wide significant associations to all three glial pathways, with strongest association to the Glia-Astrocyte
pathway (p = 0.002).
Conclusions: Consistent with findings of white matter abnormalities in schizophrenia by other methods of study, the Glia-
Oligodendrocyte pathway was associated with schizophrenia in our genomic study. These findings suggest that the
abnormalities of myelination observed in schizophrenia are at least in part due to inherited factors, contrasted with the
alternative of purely environmental causes (e.g. medication effects or lifestyle). While not the primary purpose of our study,
our results also highlight the consequential nature of alternative choices regarding pathway analysis, in that results varied
somewhat across methods, despite application to identical datasets and pathways.
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Introduction
The molecular etiologies of schizophrenia and bipolar disorder
are not yet understood, hindering efforts to develop novel
pharmacological treatments. Accordingly, pharmaceutical com-
panies have drastically reduced investment in psychiatric drug
discovery [1]. In order to develop therapeutics for the majority
fraction of patients who still do not respond adequately – or at all –
to currently available treatments, new insights into the molecular
etiology of these and other psychiatric disorders are needed.
Both schizophrenia and bipolar disorder are known to be highly
heritable, with estimates of 81% for schizophrenia and 75% for
bipolar disorder [2]. Groundbreaking discoveries about specific
genetic risk variants have occurred in the last few years. In
schizophrenia, both copy number variant (CNV) and single
nucleotide polymorphism (SNP) associations have been identified
using genome-wide methodologies [2,3]. Genome-wide associa-
tion studies (GWAS) have also identified SNPs associated with
bipolar disorder [4]. Of great importance regarding the number
and distribution of genetic risk factors, polygenic analyses suggest
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that both disorders are influenced by thousands of risk loci [3]
distributed across the genome, and further – that many loci are
shared across schizophrenia and bipolar disorder [5]. Thus,
despite these advances, efforts to understand the biological
processes and pathways affected by genetic risk variants are just
beginning. Further, as individual genes each only contribute
modestly to risk, but genotype as a whole is highly determinant of
psychotic illness, further studies of functionally related gene groups
and their interactions seem especially promising. Results of such
analyses may identify new targets for study and intervention.
Pathway analyses
One analytic approach designed to provide information about
the relevant biology implicated by genetic associations is known as
‘pathway analysis’. In contrast to typical GWAS – which evaluates
the significance of association to phenotype for each SNP
individually – pathway analyses are designed to determine the
significance of association between phenotype and variants in a
group of genes related by function. The pathway is the unit of analysis
instead of each individual SNP, one by one. Regarding
terminology, it is often technically more correct to say ‘gene set’
analyses because the term ‘pathway’ implies a more specific
relationship among genes. However, throughout this manuscript,
in keeping with common practice, we refer to ‘gene set analyses’ as
‘pathway analyses’.
It is important to note that while these pathways contain genes
that are critically important for the specified cells or processes in
question, some of the same genes may be relevant in varying
degrees for other cells and processes. Such sets of genes are an
appropriate analysis unit for disorders such as schizophrenia and
bipolar disorder that have multifactorial inheritance and are likely
due to multiple, often subtle, changes in large numbers of genes.
The combined effect of numerous disrupted genes impacting a
specific cell type or function is exactly what pathway analysis can
reveal, and the specific genes involved and their precise functions
and relationships can be refined in future studies. Of course, the
results may point to anomalies in other cell types or other
processes that share some of the same genes, and these other
processes can also be tested for disease association in further
studies.
Clearly, the power of analyzing by pathways depends on
accurate identification of genes that contribute to the specific
pathophysiology of the illness studied. Past pathway analyses of
schizophrenia have implicated synaptic, neuronal cell adhesion,
and membrane scaffolding gene sets [6,7]. The goal of the present
study is to test, in large GWAS datasets, hypotheses about the
involvement of groups of genes determining glial, mitochondrial,
and glutamate function in schizophrenia and bipolar disorder.
These pathways were chosen based on convergent evidence of
these elements being abnormal in schizophrenia and bipolar
disorder, as summarized below. Details about pathway construc-
tion are given in the methods section, and lists of genes within
pathways are provided in the data supplement (Data S1).
Glial Pathways. Both major subclasses of glial cells, oligo-
dendrocytes and astrocytes, may be altered in psychotic disorders
(for reviews of the findings cited below [8–10]). In vivo brain
imaging and post-mortem studies consistently report somewhat
reduced and disorganized white matter in psychosis, with these
abnormalities being greater in schizophrenia, but also seen in
bipolar disorder. Gene expression studies point to oligodendro-
cytes, the cells responsible for myelination and the maintenance of
white matter, as functionally abnormal in psychotic disorders.
Dysfunction in oligodendrocyte development, location, or function
(i.e. ability to make myelin) might be the cause of white matter
abnormalities in schizophrenia. Some evidence from brain
imaging and postmortem studies also suggest abnormalities in
the number or density of astrocytes, which perform crucial tasks in
stabilizing glutamatergic synapses, both in bipolar disorder and
schizophrenia. Of likely relevance, one of the most consistent
findings in psychiatric post mortem research is a reduced density
of glia in prefrontal cortex in mood disorders, including bipolar
disorder. Currently it is not definitively known if the missing cells
are astrocytes or oligodendrocytes.
Mitochondrial Pathways. The brain requires twenty times
the energy of the rest of the body (per unit weight) to maintain its
functions [11]. Energy expenditure supports maintenance of ionic
gradients across neural membranes and the recycling and
metabolism of potentially toxic neurotransmitters, including
glutamate (see below). Even a modest reduction in energy
production can lead to neuronal dysfunction by impairing the
metabolism of key compounds or reducing the production and
recovery of electrical gradients across the membranes [12].
Evidence consistent with an abnormality of energy production
has been reported both for schizophrenia (for reviews of the
evidence listed below [13–16]) and bipolar disorder (for reviews of
the evidence below [17–20]). Specifically, the evidence suggests
alterations in the function of mitochondria, which are responsible
for most cellular energy production. Findings in schizophrenia
include reduced expression of genes and proteins associated with
mitochondrial function, both in brain post mortem and in
peripheral cells. In vivo observations include low metabolic activity
and low levels of the high-energy molecule ATP in brain. Also, a
reduced density of mitochondria in peripheral cells and in
synapses, specifically, has been reported for schizophrenia and
for psychotic disorders in general. Similar evidence in bipolar
disorder includes reduced expression of genes associated with
mitochondrial function, both in post mortem brain and peripheral
cells. This is especially true for cells under stress. In addition, in vivo
brain imaging studies report elevated lactate, suggesting reduced
oxidative phosphorylation, and a slow recovery of the high-energy
storage molecule phosphocreatine after depletion by regional
brain activation. Altered mitochondrial shape, which implies
altered function, has also been observed in both brain and
peripheral cells in bipolar disorder.
Glutamate Pathway. Glutamate is the major excitatory
neurotransmitter in the brain. This role, its effects on cell growth
and its toxic properties, have all led to proposals that abnormalities
of glutamate underlie psychotic and mood disorders (For reviews
of the evidence cited here [21–24]). Psychosis and mood
dysregulation can be induced by drugs that antagonize glutamate
NMDA receptors. More recently, drugs have been developed to
modulate activity at either NMDA or metabotropic glutamate
receptors and reduce symptoms of schizophrenia and depression.
Post mortem studies suggest altered activity of glutamate synthetic
and catabolic enzymes both in schizophrenia and bipolar disorder.
Brain imaging studies also reveal abnormal levels and turnover of
glutamate and its metabolites in both disorders. Most recently,
genetic studies have reported the association of genes for
glutamatergic neurotransmission and psychotic disorders [24].
Present Study
The origin of the abnormalities noted above, and even whether
they are causal or epiphenomenal, is not known. In the present
study, we examine evidence for association between genes in these
biologically relevant pathways and both schizophrenia and bipolar
disorder. Although this is not a study of the pathway methods,
themselves, we did have to address a methodological challenge in
choice of the pathways used: while alternative pathway analysis
Pathway Analysis Implicates Glia in Schizophrenia
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methods are conceptually similar, in that they are designed to
provide composite metrics of association for sets of genes, they
provide results that are only modestly correlated with one another.
This is true because alternative pathway analysis methods
aggregate and evaluate SNP-level information in different ways.
Moreover, the ‘best’ pathway analysis method is not known, nor is
there likely a single best method, as different methods will be better
suited to detecting the as-yet-unknown genetic architectures
underlying different psychiatric disorders. Thus, we picked one
method, MAGENTA [25], for the primary analysis because it was
the first method available to our group. Through subsequent
collaborations, we then applied three additional pathway analysis
methods: ALIGATOR [26], INRICH [27], and Set Screen [28].
We expected that results would vary somewhat across the four
pathway analysis methods, but knew that any degree of consensus
would be helpful in guiding future work. The use of multiple
measures is a check on the robustness of any findings observed by
the primary analysis and could provide, in an exploratory fashion,
other leads on relevant pathways for future study.
Methods
Genotypic data for Schizophrenia and Bipolar Disorder
Publically available Psychiatric Genomics Consortium (PGC)
data were downloaded for schizophrenia [29] and bipolar disorder
[4]. The specific files used were pgc.scz.full.2012-04.txt and
pgc.bip.full.2012-04.txt, from https://pgc.unc.edu/Sharing.
php#SharingOpp. Publically available PGC datasets contain the
primary but not replication samples, and have the following
sample sizes for schizophrenia (9,394 cases/12,462 controls) and
bipolar disorder (7,481 cases/9,250 controls). These files contain
p-values for imputed SNPs and were filtered for info scores .0.8,
yielding 1,068,286 SNP-level p-values for schizophrenia and
2,088,878 SNP-level p-values for bipolar disorder. Gene bound-
aries were defined as 35 kilobases upstream of genes and 10
kilobases downstream of genes, chosen to capture most promoter
regions and cis-eQTLs [30]. All coordinates were hg18 (Human
Genome build 18). Finally, the MHC region (defined here as
chromosome 6, bases 25,000,000–35,000,000) was removed prior
to analysis given extensive linkage disequilibrium (LD) in the
region. However, none of the genes in pathways tested in this
report overlapped the HLA region, so this had no effect on our
results. No other regions or SNPs were removed from analysis.
Figure 1 depicts an example of the type of data used in this
report (i.e. SNP-level p-values from GWAS analyses). These
‘Manhattan Plots’ are a standard graphical depiction of p-values
(y-axis, in -log10 units) by chromosomal position (x-axis). Analytical
decision points in pathway analyses (e.g. how to assign SNPs to
genes) are described in the caption for Figure 1. Ricopili was used
to create the detailed Manhattan plot in Figure 1 B (http://www.
broadinstitute.org/mpg/ricopili/).
Pathway curation (i.e. creation of gene sets for analysis)
Based on prior evidence for the pathways/functional groupings
of greatest interest, we identified 262 mitochondria related, 285
glutamate related, and 110 glia related genes sets from the Gene
Ontology [31] (GO) and REACTOME [32] databases. Selected
gene sets were then combined with genes from the published
literature about other mitochondria, glutamate, and glia related
genes thought to be involved in the pathophysiology of schizo-
phrenia and/or bipolar disorder – to create the ten gene sets
analyzed in this report. We created three superordinate gene sets:
Glia, Mitochondria, and Glutamate. The superordinate Glia
pathway had two subordinate pathways (Astrocyte and Oligoden-
drocyte) and the superordinate Mitochondria pathway had five
subordinate pathways (Crista, Distribution, Fission, ‘Fission_plus’
with additional genes, and Fusion). There were no subordinate
pathways for Glutamate. Gene membership in each of the ten
pathways is provided in Data S1. A reviewer of the submitted
manuscript asked whether, given the substantial overlap in genes
used by different cells, any associations between pathways and
illness observed in this study might generalize to other cell types.
The reviewer suggested studying pathways for lymphocytes,
macrophages and hepatocytes. This is an interesting question,
especially as abnormalities of peripheral cells, as previously noted,
have been observed in psychotic and mood disorders. While the
evidence for abnormalities of CNS cells is stronger than that for
peripheral cells, we created pathways for lymphocytes, macro-
phages and hepatocytes, using the public data sets available in
Gene Ontology [31] (GO), by methods equivalent to those we
used for our primary hypotheses. Membership of genes in these
pathways is also provided in the Data S1. Analyses of these
pathways is necessarily exploratory. Per reviewer suggestion, these
exploratory analyses also serve as a negative control against the
possibility that genes (such as PPARG and SHH) – which are
important for many cell types – might result in a non-specific
association to oligodendrocytes.
Pathway analysis methods
We used four distinct and independently developed pathway
analysis methods to test hypotheses that the specified mitochon-
drial, glutamatergic, and glia-related gene sets are associated with
schizophrenia and bipolar disorder. The primary analysis method
was MAGENTA [25]. To explore sensitivity and robustness of
results to different pathway methods, we subsequently ran three
additional methods: ALIGATOR [26], INRICH [27], and Set
Screen [28]. Each analysis was run separately according to
standard protocols for that method. Set Screen requires GC-
corrected p-values to avoid spurious pathway associations arising
from aggregation of inflated test statistics; therefore lambda-
adjusted p-values were used in Set Screen analysis. Default settings
were used unless they needed to be altered to conform to the
parameters specified above.
By default, MAGENTA employs two thresholds, at ‘95%’ and
‘75%’, which specify the (somewhat arbitrary) threshold above
which a gene-level p-value will be deemed ‘significant’. Compar-
ison of the observed number of ‘significant’ genes within a
pathway to the expected number of significant genes provides the
pathway level p-value (as calculated by the MAGENTA
algorithm). The latter threshold of 75% (hereafter, ‘‘setting’’)
captures weaker signals of association than the former, and may be
better suited to detecting associations to highly polygenic
phenotypes. These two settings were also used for ALIGATOR
and INRICH. Set Screen does not have the option of specifying
settings, so only one ‘setting’ is reported for Set Screen. These
different analytic methods are expected to yield somewhat
different results, as they do not use the same assumptions nor
model the data in equivalent ways. Rather, they are complemen-
tary in seeking possible associations of pathways (gene sets) to
illness. Properties of the genome and genetic data which
necessitate analytical decisions in pathway analysis are explained
in Figure 1.
Multiple testing correction
Though three of the methods (MAGENTA, ALIGATOR, and
INRICH) provide corrected p-values or false discovery rates, none
of the methods could provide appropriate correction for the use of
two settings (95% and 75%, see above) or for the analysis of two
Pathway Analysis Implicates Glia in Schizophrenia
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Figure 1. Manhattan plots illustrating data use decisions in pathway analyses. Figure 1 utilizes a Manhattan plot of 22 chromosomes (A)
and a detailed Manhattan plot for a region of chromosome 7 (B) to illustrate differences in pathway analytic methods. One major distinction among
pathway analysis methods designed for GWAS data concerns the use of raw data (i.e. individual level genotypes) versus summary statistics (i.e. p-
value, odds ratios, betas, etc. per SNP). For example, the paper recently published by Goudriaan et al (2013) used raw genotype data. In contrast, the
four methods used in this report all use SNP-level summary statistics as input data. Figure 1A is a ’Manhattan plot, in which each point represents one
SNP. The x-axis denotes chromosomal position and the y-axis denotes significance of each SNP’s association to the phenotype (units of -log10p-
value). The horizontal red line denotes genome-wide significance (p,561028). In Figure 1B, a section of the Manhattan plot on chromosome 7 is
expanded, and the location of genes is given in the lower portion of section 1B. As seen in 1B, individual genes may contain many SNPs (colored
diamonds in figure). Three of the pathway analytic methods used in this report use a ‘best SNP per gene/region’ approach, meaning that they ‘count’
only the most significant SNP in a gene or region of interest (methods MAGENTA, ALIGATOR, and INRICH). In contrast, Set Screen utilizes information
from all SNPs within a gene or region of interest in the calculation of pathway-level statistics. Another aspect of the design of pathway analyses is
illustrated in 1B: correlation among SNPs. Due to the haplotype structure of chromosomes, many genetic variants are correlated with one another,
and are said to be in ‘linkage disequilibrium’ or ‘LD’. Thus, each method used in this report has analytic procedures for handling LD, so that correlated
signals are not inappropriately counted multiple times. As stated in the text, correlation among SNPs is so extensive in the HLA region of
chromosome 6, that pathway analytic methods currently exclude this region from analysis. In the past, failure to exclude the HLA from pathway
analyses led to the reporting of spurious associations. Finally, we note that assigning of SNPs to genes is an imprecise task. Two complications are
overlapping genes and correlated variants that may span many genes. A more daunting challenge is capturing the regulatory elements that impact
genes. Such elements may be located far from genes, sometimes even on different chromosomes. Future developments in pathway analytic methods
will likely make use of information about tissue and gene-specific regulatory elements (e.g. derived from the ENCODE project), but such information
is not currently implemented in these pathway analytic methods.
doi:10.1371/journal.pone.0089441.g001
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different datasets (schizophrenia and bipolar disorder). We use
Bonferoni correction within method (e.g. for our primary analysis
with MAGENTA), acknowledging that it is conservative given
non-independence of genes within pathways and use of data across
alternative settings (95% vs. 75%). There is no perfect way to
correct for all 140 tests conducted in this report, but we apply
FDR [33] control using an R [34] library (‘qvalue’) from
Bioconductor [35]. Tables S2 and Table S3 provide q-values
corresponding to all p-values for schizophrenia and bipolar
disorder, respectively. Additional details about the application of
FDR control in this report are provided in Methods S1 and
Figure S1.
Results
Primary Analysis
Our primary analyses were performed with MAGENTA. The
strongest result was an association between the Glia-Oligoden-
drocyte pathway and schizophrenia (p = 0.0005). This p-value is
significant after conservative Bonferroni correction in our primary
(MAGENTA) analysis for 40 tests (10 pathways * 2 settings * 2
disorders). Within the primary analyses, while there were trends of
interest, no other pathways were method-wide or nominally
significant. Gene-level p-values and other information about the
52 genes in the Glia-Oligodendrocyte pathway are provided in
Table S1.
Interestingly, the strongest results for the MAGENTA analyses
were obtained with the 75% setting, which is effectively a user-
defined threshold for gene-level for significance. It is important to
note that the use of the alternative (here 75% vs. 95%) threshold is
not a more lenient threshold for statistical significance. Rather,
adjustment of this setting allows the user to optimize the
MAGENTA algorithm for the expected genetic architecture
and/or expectations about the data being analyzed. As stated in
the MAGENTA script, users may want to rely on the 75% setting
for diseases that are known to have highly polygenic genetic
architectures. This is the case for schizophrenia.
Another important point pertains to the data being analyzed.
For example, in the case of a somewhat underpowered GWAS, p-
values for true risk alleles may be relatively unimpressive, and odds
ratios will not even demonstrate the expected direction of effect on
a reliable basis.
Therefore, casting a wider net (via use of a 75% threshold) may
allow for better capture of weak signals, which in aggregate are
indicative of association. Given what is now known about
schizophrenia, both extreme polygenecity and low power to
detect the association of individual alleles are likely true. The latter
is another reason why larger GWAS samples are needed to
provide appropriate replication and clarification of these findings.
Secondary analysis
Secondary analyses, to test for robustness of the primary
findings and as an exploration of alternative pathways to be
explored in future studies, were conducted with ALIGATOR,
INRICH, and Set Screen. Consistent with the MAGENTA
results, the Glia-Oligodendrocyte pathway in the schizophrenia
dataset obtained nominally significant p-values using ALIGATOR
and INRICH (p= 0.022 and 0.006, respectively); see Tables 1 &
2. Further, in both cases the more inclusive setting yielded stronger
p-values, indicating more highly polygenic genetic architecture
and/or lower power in the schizophrenia GWAS results see
Tables 1 & 2.
Across all secondary analyses, ALIGATOR and INRICH
results were similar, but not as strong, as the MAGENTA results.
In contrast, eight of twenty pathways tested across the schizo-
phrenia and bipolar disorder datasets were at least nominally
significant according to Set Screen analysis. For schizophrenia, Set
Screen yielded nominally significant associations for a total of five
glial and mitochondrial pathways: superordinate Glia (p = 0.012),
Glia-Astroctye (p = 0.007), Mitochondria-Crista (p = 0.011), Mito-
chondria-Fission (p= 0.035), and the larger Mitochondria-Fis-
sion_plus pathway (p = 0.031). For bipolar disorder, all three glial
pathways were at least nominally significant. The Glia-Astrocyte
pathway was method-wide significant (p = 0.002) whereas the
Glia-Oligodendrocyte (p = 0.021) and superordinate Glia
(p = 0.025) pathways were both nominally significant.
In an effort to determine how many results in this report are
likely to be true, we used the FDR control procedures described by
Storey, Tibshirani, and Dabney [35,33]. These procedures allow
for the estimation of the number of true results in this report,
which is four (4). Q-values corresponding to all p-values (for
schizophrenia and bipolar disorder) are provided in Tables S2
and Table S3.
As mentioned, after the completion of our primary and
secondary analyses, we explored the association of pathways for
peripheral cells, which share some relevant genes with brain cells,
with schizophrenia and bipolar disorder. No significant associa-
tions were observed. Details are provided in theMethods S1 and
Table S4.
Conclusions
The observed Glia-Oligodendrocyte pathway association to
schizophrenia is consistent with an extensive literature confirming
white matter abnormalities in schizophrenia [36]. These abnor-
malities are observed in living patients via brain imaging and also
in postmortem analyses. White matter is composed of axons
surrounded by myelin produced by oligodendrocytes. If supported
in future replication attempts, this finding represents one of the
first links for schizophrenia between specific neurobiological
findings and specific sets of genes, as assessed in large-scale
genetic studies. In all, given the prior evidence implicating
oligodendrocytes and the current evidence that genes related to
oligodendrocytes are associated with schizophrenia, an oligoden-
drocyte pathology seems well supported. Future studies might
narrow down the most relevant genes and their relationship to the
cellular processes that result in disrupted myelination in schizo-
phrenia. It might also be possible to link this pathway and
associated abnormalities in oligodendrocytes to the high-level, core
features of schizophrenia thought to be based on white matter
pathology; for example: disrupted connectivity of regional brain
activity and reduced co-ordination of thinking.
The bipolar disorder finding of association to astrocyte
development and function genes (observed only with Set Screen)
is also intriguing. As noted above, astrocytes may be among the
reduced glial cells observed in bipolar disorder [37]. In addition,
astrocytes form a tripartite synapse with glutamatergic terminals
and postsynaptic densities in the brain and also play a direct role in
glutamate metabolism. Thus, astrocyte abnormalities could
explain some of the glutamatergic anomalies reported in psychosis
and mood disorders. Specifically, some portion of altered
glutamatergic signaling may be due to impaired glutamate uptake
and recycling by astrocytes, rather than being due to abnormalities
of either glutamate release or glutamate receptors (in pre and/or
post synaptic neurons).
Finally, in the secondary analyses, we note that Set Screen
results suggested nominally significant associations for mitochon-
drial fission and mitochondrial cristae in schizophrenia. It is
important to note the higher likelihood of false positive results in
Pathway Analysis Implicates Glia in Schizophrenia
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secondary analyses. However, mitochondrial abnormalities have
been reported previously in schizophrenia and bipolar disorder.
Replication studies with larger samples will provide evidence
about the reliability of our findings that specific mitochondrial
gene sets may be related to these abnormalities.
The most important consequence of all of these findings and
trends may be their biological relevance, specifically their
implications concerning etiology and pathophysiology. Psychotic
disorders, including schizophrenia, are highly complex by cause
and course. They are known to have inherited determinants, but
they are also associated with infectious, toxic and traumatic
exposure. In addition, life style, life events, and treatment can alter
brain biology in those who develop psychosis. For this reason, in
vivo brain imaging and post mortem studies are limited in
determining if abnormalities observed exist prior to the onset of
overt illness or are a consequence or concomitant of illness. These
genomic results strongly suggest that some factors, notably those
for the function of glial elements in brain, are true risk factors for
illness.
Comparison of results from different pathway analysis
methods
We realize that the concordant and discordant results obtained
from the separate analytic methods is a phenomenon that is
interesting in and of itself. While these differences are expected
and further study of the reasons for these differences is an
Table 1. Schizophrenia pathway p-values by method and setting.
Primary Analysis Seondary Analyses
MAGENTA ALIGATOR INRICH SS
Genes 95% 75% 95% 75% 95% 75% –
GLIA 146 0.54 0.06 0.40 0.18 0.29 0.34 0.012#
Glia – Oligodendrocyte 52 0.48 0.0005* 0.21 0.022# 0.17 0.006# 0.14
Glia – Astrocyte 42 0.89 0.24 N/A 0.51 0.74 0.68 0.007#
MITOCHONDRIA 74 1.00 0.06 N/A 0.31 0.53 0.66 0.23
Mitochondria – Crista 6 0.22 0.36 N/A 0.60 1.00 0.51 0.011#
Mitochondria – Distribution 7 1.00 0.38 N/A 0.65 1.00 1.00 0.12
Mitochondria – Fission 12 1.00 0.96 N/A N/A 1.00 1.00 0.035#
Mitochondria – Fission 959 24 0.69 0.54 N/A 0.50 0.34 0.61 0.031#
Mitochondria – Fusion 9 1.00 0.32 N/A 0.44 1.00 0.39 0.08
GLUTAMATE 158 0.85 0.45 0.86 0.54 0.46 0.88 0.19
SS = Set Screen.
* Denotes method-wide significance, meaning correction for all tests conducted with a given method. For MAGENTA, ALIGATOR, and INRICH, correction is for 40 tests
(a= 0.00125 given 10 pathways62 settings62 disorders). Set Screen correction is for 20 tests given single setting (a=0.0025).
# Denotes nominal significance (p,0.05).
doi:10.1371/journal.pone.0089441.t001
Table 2. Bipolar disorder pathway p-values by method and setting.
Primary Analysis Secondary Analyses
MAGENTA ALIGATOR INRICH SS
Genes 95% 75% 95% 75% 95% 75% –
GLIA 146 0.92 0.42 0.68 0.59 0.62 0.86 0.025#
Glia – Oligodendrocyte 52 0.93 0.19 0.41 0.48 0.45 0.64 0.021#
Glia – Astrocyte 42 0.88 0.46 0.46 0.20 1.00 0.80 0.002*
MITOCHONDRIA 74 1.00 0.73 0.92 0.74 0.82 0.70 0.51
Mitochondria – Crista 6 1.00 0.37 N/A 0.19 1.00 0.34 0.82
Mitochondria – Distribution 7 1.00 0.17 N/A 0.37 1.00 0.25 0.20
Mitochondria – Fission 12 1.00 0.47 N/A 0.51 1.00 0.51 0.99
Mitochondria – Fission 959 24 0.68 0.67 N/A 0.65 0.24 0.62 0.97
Mitochondria – Fusion 9 1.00 0.87 N/A 0.63 1.00 1.00 0.44
GLUTAMATE 158 0.74 0.63 0.78 0.29 0.37 0.17 0.49
SS = Set Screen.
*Significant within method, meaning correction for all tests conducted with a given method. For MAGENTA, ALIGATOR, and INRICH, correction is for 40 tests
(a= 0.00125 given 10 pathways62 settings62 disorders). Set Screen correction is for 20 tests given single setting (a=0.0025).
# Nominal significance (p,0.05).
doi:10.1371/journal.pone.0089441.t002
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important area of study in the development and interpretation of
pathway analysis, such comparisons are beyond the scope of this
paper. They would require extensive modeling and are properly
the subject of other papers. Our study used established pathway
techniques to gain insight into the association of gene sets and
psychotic disorders. We used a primary analysis (MAGENTA) and
secondary analyses for possible confirmation or expansion of
evidence of associations, not to provide a comparison of
techniques.
That being said, we found evidence supporting the expectation
that selection of pathway analysis method, and the settings used
within methods, is not trivial. Indeed, we would have reached
somewhat different conclusions about the association of these
pathways with schizophrenia and bipolar disorder if we had
applied only one method. This means that replication attempts of
pathway analyses should be conducted using the same method and
same settings as the original report if direct comparisons are to be
made. However, these results also suggest real value in applying
more than one method, so that clues to pathway associations are
not missed by the limitations of any one method.
Across the four methods, which set of results is ‘right’? In one
sense, they all are. Each of these methods is a valid approach to
pathway analysis that creates and evaluates pathway level statistics
from the relevant GWAS data. There is undoubtedly variability in
the degree to which each method accurately captures genetic
signals within pathways, but currently there is no ‘gold standard’.
Rather, the suitability of any particular pathway analysis method
will vary across pathways and phenotypes because of the
(presumably) different underlying genetic architectures (See
Figure 1). More and separate research is needed to determine
which pathway analysis method is best, for which diseases and
which datasets, and what criteria should be used for choosing a
method in each case. As noted, resolving these issues will require
the use of multiple real data sets as well as simulations and, as such,
are well beyond the focus of this report.
However, it is worth noting that the pattern of correlations
across results from the four methods is broadly consistent with
major similarities and differences among pathway analysis
methods used in this report. Whereas Set-screen uses all p-values
within all genes in the calculation of pathway-level p-values,
ALIGATOR, INRICH, and MAGENTA use a ‘‘best-SNP per
gene’’ approach. Further, the latter three methods may be
classified as ‘‘over-representation’’ methods, which test the
number of genes in a pathway that reach a given significance
threshold, with no further differentiation among p-values above
the specified threshold. These major distinctions likely explain why
Set Screen results were least like results from the other three
methods. For additional information about similarities and
differences among these methods, please see a text section
‘Pathway analysis method comparison’ in the Methods S1.
Limitations
Our findings represent one attempt to seek associations between
illness and groups of genes (pathways) chosen on the basis of
independent evidence for likely mechanistic involvement in
schizophrenia and/or bipolar disorder. The findings, as always,
need to be subjected to a replication attempt, in an independent
dataset of adequate size, and using the same methods and
parameters. No dataset meeting these criteria is currently
publically available. The ‘PGC29 – Psychiatric GWAS/Genomic
Consortium 2– schizophrenia dataset will be available in the future
and is ideal for this application. Also regarding datasets, some
common control subjects are included in the publically available
PGC schizophrenia and bipolar disorder datasets. This should not
pose a problem for interpretation of our results because shared
controls would tend to make results for the two disorders more
similar than they actually are. Of note, for the method-wide
significant results, we found no evidence of overlapping associa-
tions between the two disorders. We cannot rule out the possibility
that the non-significant trends observed across classes of glia are an
example of such similarities introduced by the existence of some
shared controls. However, these trends may also accurately reflect
shared determinants of various psychotic disorders.
While our manuscript was under review, an independent group
reported their results showing association between glial pathways
and schizophrenia [38]. These results were by a different analysis
that used genotype-level data from participants. This represents
further evidence in support of the association observed. Combined
with the other biological data on the involvement of oligocuytes in
schizophrenia, the evidence is highly suggestive of a key role for
these cells in determining expression of illness.
Regarding the gene sets themselves, it must be noted that
pathway curation relies on incomplete information from diverse
sources, of variable quality. Therefore we cannot know how well
gene membership within pathways accurately reflects biologic
function. However, every gene listed in a pathway is in the list
because there is data supporting its inclusion. Below we discuss
ways in which pathways may be refined in the future. Regarding
phenotype, we could not interrogate questions regarding pheno-
typic heterogeneity because the GWAS phenotype was binary (i.e.
schizophrenia or bipolar case vs. control). Further, were not able
to select the covariates used to generate the publically available
GWAS data, given that it is a static resource.
Lastly, we are aware that few genes and no gene sets are
uniquely important to any cell type or cell function. Biology, by its
nature, uses the same elements in diverse instances and interactive
ways. The finding that particular gene sets, such as the
oligodendrocyte pathway studied here, are associated with illness
is strong evidence for a pathophysiologic role of these cells,
especially as it is consistent with other evidence from independent
studies performed using entirely different technologies. It does not
rule out the likelihood that some of these same genes may be
involved in other defects observed in schizophrenia, both in the
CNS and peripheral cells.
Final synopsis
Negative results from these analyses are, unfortunately, not
entirely informative because it could be the case that pathways
were not well specified or that power was low. However, positive
findings for the Glia-Oligodendrocyte pathway in schizophrenia
and, with less certainty, the Glia-Astrocyte pathway in bipolar
disorder offer confirmation of neurobiological findings about these
disorders, and are important targets for replication attempts and
the design of new studies. Replication attempts can occur
alongside efforts to perform more refined pathway analyses based
on these results. For example, one could trim the associated
pathway lists to exclude genes that contributed little or detracted
from observed associations, and then test these ‘short lists’ in
independent GWAS datasets. It is also possible to examine subsets
of the genes for associations to specific features of illness,
measurable by other technologies, such as white matter integrity
or glial health. Mitochondrial function can be assessed in patients
or in samples derived from those patients, including the possibility
of examining patient-derived glial cells via induced pluripotent
stem cell (IPSC) technology [39]. This approach might yield even
stronger associations and more mechanistically meaningful infor-
mation about the molecular and cellular processes underlying
psychosis. In this way, these genomic results can lead to a wealth of
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complementary in vivo (eg, brain imaging) and ex vivo (eg, tissue
culture) analyses on some of the contributing causes of psychoses.
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